The problem with glycopeptides

被引：29

作者：

Gould, I. M. ^{[1
]}

机构：

[1] Aberdeen Royal Infirm, Dept Med Microbiol, Aberdeen AB25 2ZN, Scotland

来源：

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS | 2007年 / 30卷 / 01期

关键词：

D O I：

10.1016/j.ijantimicag.2007.03.006

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

引用

页码：1 / 3

页数：3

共 36 条

[1] [Anonymous], 46 INT C ANT AG CHEM
[2] [Anonymous], 2002, MMWR MORB MORTAL WKL, V51, P565
[3] Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers
Benvenuto, Mark
Benziger, David P.
Yankelev, Sara
Vigliani, Gloria
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (10) : 3245 - 3249
[4] Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus
Charles, PGP
Ward, PB
Johnson, PDR
Howden, BP
Grayson, ML
[J]. CLINICAL INFECTIOUS DISEASES, 2004, 38 (03) : 448 - 451
[5] Comparison of four methods for detection of teicoplanin resistance in methicillin-resistant Staphylococcus aureus
Charlesworth, R.
Warner, M.
Livermore, D. M.
Wilson, A. P. R.
[J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2006, 58 (01) : 186 - 189
[6] *CLIN LAB STAND I, 2006, M100S16 CLSI
[7] DAVEY PG, 1991, J ANTIMICROB CHEM SB, V27, P51
[8] PROTEIN-BINDING AND SERUM BACTERICIDAL ACTIVITIES OF VANCOMYCIN AND TEICOPLANIN
DYKHUIZEN, RS
HARVEY, G
STEPHENSON, N
NATHWANI, D
GOULD, IM
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (08) : 1842 - 1847
[9] STAPHYLOCOCCUS-AUREUS ENDOCARDITIS - COMBINED THERAPY WITH VANCOMYCIN AND RIFAMPIN
FAVILLE, RJ
ZASKE, DE
KAPLAN, EL
CROSSLEY, K
SABATH, LD
QUIE, PG
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1978, 240 (18): : 1963 - 1965
[10] A 1 year surveillance study of glycopeptide-intermediate Staphylococcus aureus strains in a French hospital
Garnier, F
Chainier, D
Walsh, T
Karlsson, A
Bolmström, A
Grelaud, C
Mounier, M
Denis, F
Ploy, MC
[J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2006, 57 (01) : 146 - 149

← 1 2 3 4 →